IONIS-GCCRRx
| Clinical data | |
|---|---|
| Other names | ISIS-426115; ISIS-GCCRRx |
| Drug class | Antiglucocorticoid |
| Identifiers | |
| UNII | |
IONIS-GCCRRx, also known as ISIS-426115, is an antiglucocorticoid which is under development by Ionis Pharmaceuticals (formerly Isis Pharmaceuticals) for the treatment of diabetes mellitus type 2.[1][2] It has also been under investigation for the treatment of Cushing's syndrome, but no development has been reported.[1] The drug is an antisense oligonucleotide against the glucocorticoid receptor.[1] As of December 2017, it is in phase II clinical trials for diabetes mellitus type 2.[1]
References
- 1 2 3 4 "IONIS GCCRRx". AdisInsight. Springer Nature Switzerland AG.
- ↑ Chikara G, Sharma PK, Dwivedi P, Charan J, Ambwani S, Singh S (April 2018). "A Narrative Review of Potential Future Antidiabetic Drugs: Should We Expect More?". Indian Journal of Clinical Biochemistry. 33 (2): 121–131. doi:10.1007/s12291-017-0668-z. PMC 5891460. PMID 29651202.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.